BSX · News · 20260817N

Watchman Demand Slowdown

BOSTON SCIENTIFIC CORP · 2026-08-17 · Importance 20 · Surprise 24

Aristotle Capital Management’s Core Equity Fund sold its Boston Scientific position because of concerns about slowing growth in the company’s Watchman and Farapulse medical-device franchises. Watchman growth is declining amid changes in implantation modalities and continued market hesitation, despite positive clinical-trial data. Farapulse is facing increased competition, which the fund believes could delay recovery in investor confidence and Boston Scientific’s premium valuation.

Key facts

• Aristotle Capital Management's Core Equity Fund sold its position in Boston Scientific Corporation. source
• Watchman's growth is declining due to implantation modality changes and market hesitation. source
• Farapulse faces increased competition. source